Ekso Bionics Holdings, Inc. specializes in the development of exoskeleton technology aimed at enhancing mobility for individuals with physical disabilities. The company operates primarily in the United States and has a unique competitive advantage in its proprietary robotic exoskeletons, which are designed for rehabilitation and industrial applications.
Business Overview
Ekso Bionics generates revenue through the sale of its advanced exoskeleton devices, which are priced at a premium due to their innovative technology. The company also benefits from service contracts and research collaborations, leveraging its expertise in robotics and rehabilitation.
Regulatory approvals for new exoskeleton models
Partnerships with rehabilitation centers and hospitals
Advancements in technology that enhance product capabilities
Market adoption rates in the healthcare sector
Risk Factors
Technological disruption from competitors developing superior exoskeletons
Regulatory changes that could impact product approvals
Emergence of new entrants in the exoskeleton market
Price competition from established medical device manufacturers
Potential liquidity issues due to lack of consistent revenue streams
Dependence on external funding for R&D initiatives
Macro Sensitivity
moderate - the demand for rehabilitation technologies is somewhat correlated with healthcare spending, which can be influenced by economic cycles.
Low - the business is not heavily reliant on debt financing, and interest rates have minimal impact on consumer demand for medical devices.
minimal - the company does not have significant credit dependencies.
Profile
growth - investors are likely attracted to the potential for high growth in the rehabilitation technology market.
high - the stock has shown significant price volatility, reflecting the speculative nature of the medical device sector.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
